July 14, 2015
Authored and Edited by Daniel F. Klodowski; Elliot C. Cook; Aaron L. Parker
In the 36 Final Written Decisions issued by the Patent Trial and Appeal Board in June, the Board cancelled 446 (86.27%) of the instituted claims, and it held that 47 (9.09%) of the instituted claims were not proven unpatentable by a preponderance of the evidence. Patent owners conceded 24 (4.64%) of the instituted claims through motions to amend.
On a per-case basis, no instituted or substitute claims survived in 26 (72.22%) of the decisions, all instituted claims survived in 5 (13.89%) of the decisions, and a mixed outcome occurred in 5 (13.89%) of the decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Board decision.
More detailed cumulative statistics on the Board’s IPR and CBM decisions, updated through July 1, 2015, are available here on the AIA Blog.
Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.